Samsung Biologics posts Q2 2026 record results with KRW 1,321 billion revenue, KRW 586 billion operating profit
AI Market Summary
Samsung Biologics reported record Q2'26 revenue and operating profit, alongside a higher cumulative contract backlog and reiterated intent to reach the upper end of 2026 guidance. Operational execution across Plants 1–4 and accelerating Plant 5 PPQ de-risk near-term capacity ramp, while the PolyPeptide acquisition adds modality breadth. The update supports confidence in sustained CDMO demand and expansion execution, directly benefiting Samsung-related equity exposure.
Impact level
● Low
Affected assets
NCSKSAMSUNG2USD/USDT+0.83%
AI Insight · NCSKSAMSUNG2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Samsung Biologics (KRX: 207940.KS) reported record second-quarter 2026 revenue of KRW 1,321 billion and operating profit of KRW 586 billion, and said cumulative contract value for the first half reached USD 21.6 billion. The company said Plant 5’s Process Performance Qualification (PPQ) work accelerated, while its all-cash public tender offer for PolyPeptide Group is expected to be completed toward the end of 2026. Samsung Biologics reiterated it remains on track to achieve the upper end of its previously announced 2026 guidance. The company said the results reflect sustained strength in its CDMO business and execution of global expansion plans.
